Literature DB >> 21712756

Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation--a propensity score analysis with 23 years of follow-up.

Yijiang Li1, Jens Gottlieb, Donghui Ma, Christian Kuehn, Martin Strueber, Tobias Welte, André R Simon, Georg Warnecke, Axel Haverich.   

Abstract

BACKGROUND: To determine whether the hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin has a graft-protective effect, we retrospectively analyzed 502 patients who had undergone lung transplantation in Hannover.
METHODS: Propensity scores have been calculated for each patient and compared between two groups. Cox Hazard analyses were performed for different parameters (e.g., basic parameters of patients, underlying diagnoses, different operations, and important organ functions after lung transplantation). Lung function after transplantation was monitored using repeated measurement analyses. Additionally, conditional Kaplan-Meier survival analyses were used to explore the impact of different diagnoses, the severity of bronchiolitis obliterans, the type of transplantation, and different immunosuppressant regimes on patient survival.
RESULTS: The results indicate a strong association between the postoperative administration of statins and the improvement of survival, maintenance of graft (lung) function, and slowing of the onset of bronchiolitis obliterans.
CONCLUSION: These findings suggest a new postoperative therapeutic focus for maintaining graft function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21712756     DOI: 10.1097/TP.0b013e318225670d

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Using human experience to identify drug repurposing opportunities: theory and practice.

Authors:  D Cavalla
Journal:  Br J Clin Pharmacol       Date:  2019-02-03       Impact factor: 4.335

Review 2.  Prevention of chronic rejection after lung transplantation.

Authors:  Anke Van Herck; Stijn E Verleden; Bart M Vanaudenaerde; Geert M Verleden; Robin Vos
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 3.  Immunosuppression in lung transplantation.

Authors:  Jenna L Scheffert; Kashif Raza
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

Review 4.  Non-pulmonary complications after lung transplantation: Part I.

Authors:  Rohan Kanade; Aditya Kler; Amit Banga
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-10-08

5.  Pretransplant dyslipidaemia determines outcome in lung transplant recipients.

Authors:  Urs Wenger; Silvia R Cottini; Georg Noll; Stefan Arndt; Paul A Stehberger; Stefanie Klinzing; Reto A Schuepbach; Markus Béchir
Journal:  Lipids Health Dis       Date:  2013-04-23       Impact factor: 3.876

Review 6.  Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.

Authors:  Alexios S Antonopoulos; Marios Margaritis; Regent Lee; Keith Channon; Charalambos Antoniades
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Immunosuppressive strategies in lung transplantation.

Authors:  Paul A Chung; Daniel F Dilling
Journal:  Ann Transl Med       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.